ReviewBiomedicines2024

Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment.

Shi-Hsun Chiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.